公开(公告)号：US20170056510A1

公开(公告)日：2017-03-02

申请号：US14917387

申请日：2016-03-08

申请人： Dinesh U. Chimmanamada ,  Weiwen Ying ,  Junyi Zhang ,  Teresa Kowalczyk-Przewloka ,  Jun Jiang ,  Sami Osman ,  Genliang Lu ,  Dharma Vutukuri ,  James Loch ,  Shoujun Chen

发明人： Dinesh U. Chimmanamada ,  Weiwen Ying ,  Junyi Zhang ,  Teresa Kowalczyk-Przewloka ,  Jun Jiang ,  Sami Osman ,  Genliang Lu ,  Dharma Vutukuri ,  James Loch ,  Shoujun Chen

IPC分类号： A61K47/48 ,  A61K31/454 ,  A61K31/519 ,  A61K31/513 ,  A61K31/4184 ,  A61K31/167 ,  A61K31/58 ,  A61K31/4545 ,  A61K31/704 ,  A61K31/497 ,  A61K31/42 ,  A61K31/4188 ,  A61K31/495 ,  A61K31/506 ,  A61K31/565 ,  A61K38/05 ,  A61K31/4745

摘要： The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

公开(公告)号：US20050250802A1

公开(公告)日：2005-11-10

申请号：US11181098

申请日：2005-07-14

申请人： James Loch ,  George Mullen ,  Eifion Phillips

发明人： James Loch ,  George Mullen ,  Eifion Phillips

IPC分类号： C07D491/20 ,  A61K20060101 ,  A61K31/439 ,  A61K31/4747 ,  A61P20060101 ,  A61P1/04 ,  A61P25/00 ,  A61P25/04 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  A61P43/00 ,  C07B61/00 ,  C07D20060101 ,  C07D471/14 ,  C07D491/22

CPC分类号： C07D491/22

摘要： Methods for the treatment of psychotic or intellectual impairment disorders with compounds of formula I, wherein A, R and R1 are as defined in the specification.

摘要翻译： 用式I化合物治疗精神病或智力障碍障碍的方法，其中A，R和R 1如说明书中所定义。